IP Library Granted Patent US 11,911,401
Granted Patent B2
US 11,911,401 · App. 17/570,054 · Granted Feb 27, 2024

Tryptamine compositions for enhancing neurite outgrowth

Inventor: Paul Edward Stamets (Shelton, WA)
Assignee: TURTLE BEAR HOLDINGS, LLC
A61K31/661A61K9/08A61K31/05A61K31/352A61K31/4045A61K31/455A61K36/06A61K36/066A61K36/07A61K36/185A61K36/73A61P25/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,911,401
App. No.
17/570,054
Granted
Feb 27, 2024
Kind
B2
Abstract

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

Claims (19)

1. A pharmaceutical composition comprising:

0.1 mg to 10 mg of ketamine, a pharmaceutically acceptable salt thereof, or a combination thereof; and

0.1 mg to 10 mg of niacin.

2. The composition of claim 1 , further comprising 0.1 mg to 10 mg of norpsilocin, a pharmaceutically acceptable salt thereof, or a combination thereof.

3. The composition of claim 1 , further comprising 0.1 mg to 10 mg of psilocin or psilocybin, a pharmaceutically acceptable salt thereof, or a combination thereof.

4. The composition of claim 1 , further comprising 0.1 mg to 10 mg of baeocystin, a pharmaceutically acceptable salt thereof, or a combination thereof.

5. The composition of claim 1 , further comprising 0.1 mg to 10 mg of norbaeocystin, a pharmaceutically acceptable salt thereof, or a combination thereof.

6. The composition of claim 1 , further comprising 0.1 mg to 10 mg of aeruginascin, a pharmaceutically acceptable salt thereof, or a combination thereof.

7. The composition of claim 1 , wherein the composition further comprises one or more pharmaceutically acceptable excipients.

8. The composition of claim 1 , wherein the composition is a powder admixture, liquid, suspension, or emulsion.

9. The composition of claim 1 , wherein the composition is a pharmaceutical dosage form in a capsule.

10. The composition of claim 1 , wherein the composition is effective to induce neurite growth and neurite lengthening in a subject in need thereof.

11. A pharmaceutical composition comprising:

0.1 mg to 10 mg of ketamine, a pharmaceutically acceptable salt thereof, or a combination thereof;

0.1 mg to 10 mg of niacin; and

0.1 mg to 10 mg of a tryptamine selected from norpsilocin, psilocin or psilocybin, baeocystin, norbaeocystin, aeruginascin, or a pharmaceutically acceptable salt thereof.

12. The composition of claim 11 , wherein the composition further comprises one or more pharmaceutically acceptable excipients.

13. The composition of claim 11 , wherein the composition is a powder admixture, liquid, suspension, or emulsion.

14. The composition of claim 11 , wherein the composition is effective to induce neurite growth and neurite lengthening in a subject in need thereof.

Continuity (4)
Continuation 16951009 · Nov 18, 2020
Provisional Application 63007482 · Apr 9, 2020
Provisional Application 62937536 · Nov 19, 2019
Related Publication 20220125809A1 · Apr 28, 2022